248 related articles for article (PubMed ID: 35227966)
41. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
44. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
[TBL] [Abstract][Full Text] [Related]
45. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands.
Ten Berge DMHJ; Damhuis RAM; Aerts JGJV; Dingemans AC
Lung Cancer; 2023 Jul; 181():107253. PubMed ID: 37236088
[TBL] [Abstract][Full Text] [Related]
46. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E; Shaw AT; Bearz A; Camidge DR; Solomon BJ; Bauman JR; Bauer TM; Peters S; Toffalorio F; Abbattista A; Thurm H; Peltz G; Wiltshire R; Besse B
Ann Oncol; 2021 May; 32(5):620-630. PubMed ID: 33639216
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract][Full Text] [Related]
48. Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Velthaus JL; Iglauer P; Simon R; Bokemeyer C; Bannas P; Beumer N; Imbusch CD; Goekkurt E; Loges S
Oncol Res Treat; 2021; 44(9):495-502. PubMed ID: 34320493
[TBL] [Abstract][Full Text] [Related]
49. Lorlatinib in ROS1-positive NSCLC.
Killock D
Nat Rev Clin Oncol; 2020 Jan; 17(1):7. PubMed ID: 31705129
[No Abstract] [Full Text] [Related]
50. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
51. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
52. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
53. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report.
Mawet M; Basse C; Barrois M; Gligorov J; Cadranel J; Chabbert-Buffet N; Selleret L
J Gynecol Obstet Hum Reprod; 2023 Dec; 52(10):102673. PubMed ID: 37777070
[TBL] [Abstract][Full Text] [Related]
54. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
55. Later-Line Treatment with Lorlatinib in
Hochmair MJ; Fabikan H; Illini O; Weinlinger C; Setinek U; Krenbek D; Prosch H; Rauter M; Schumacher M; Wöll E; Wass R; Brehm E; Absenger G; Bundalo T; Errhalt P; Urban M; Valipour A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171712
[TBL] [Abstract][Full Text] [Related]
56. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
57. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
58. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Lu S; Zhou Q; Liu X; Du Y; Fan Y; Cheng Y; Fang J; Lu Y; Huang C; Zhou J; Song Y; Wang K; Pan H; Yang N; Li J; Chen G; Chang J; Cui J; Liu Z; Bai C; Zhang H; Zhao H; Zhang K; Peltz G; Li H; Wu YL
J Thorac Oncol; 2022 Jun; 17(6):816-826. PubMed ID: 35307611
[TBL] [Abstract][Full Text] [Related]
59. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
60. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
